Depression

Adjunctive rTMS for treatment-resistant depression? Researchers performed a meta-analysis of 19 randomized sham-controlled trials.

Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.

The relationship of this key symptom of major depressive disorder and patient burden is not well understood. These two posters covered it.

“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

How can augmenting conventional antidepressants with creatine monohydrate help patients with depression?

The drug’s developers respond to the FDA’s decision to deny approval and consider future directions for this indication.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

The treatment was well-tolerated, and no serious treatment-emergent adverse effects were identified.

What is new in research on major depressive disorder?

You've heard about winter seasonal affective disorder, but what about summer?

Psychiatry: a field of medicine that is constantly evolving.

The FDA did not grant approval for the treatment for major depressive disorder.

In the largest study of its kind to date, researchers found promising results for subcutaneous ketamine for treatment resistant depression.

A new cognitive biotype for depression may impact symptoms and treatment outcomes.

From a look at adolescent substance use to special challenges in treating borderline personality disorder during the perinatal period, here are highlights from the week in Psychiatric Times.

The drug has shown statistically significant, clinically meaningful reductions in symptoms of depression, anhedonia.

Did you miss our APA Annual Meeting coverage?

What is the association between the gut microbiome and response to SSRIs in patients with depression?

Research using data from the All of Us Research Program seeks to solve the mystery of what makes medications work for some and not others.

Experts discuss how practitioners are viewing major depressive disorder (MDD) as a chronic condition vs an episodic condition.

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss navigating the challenge of a “one size fits all approach” when treating and identifying the specific needs of patients with major depressive disorder (MDD).

Here’s everything you need to know to about how to integrate apps into your clinical practice.

From research updates on at-home ketamine use to the effects of comorbid depression and anxiety on insomnia treatment, here are highlights from the week in Psychiatric Times.

Fatigue: a very common physical complaint that often accompanies depressive disorders.